Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash & Equivalents (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Cash & Equivalents for 12 consecutive years, with $130.9 million as the latest value for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 15.0% year-over-year to $130.9 million; the TTM value through Mar 2026 reached $130.9 million, down 15.0%, while the annual FY2025 figure was $134.9 million, 12.43% down from the prior year.
  • Cash & Equivalents hit $130.9 million in Q1 2026 for Syndax Pharmaceuticals, down from $134.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $295.4 million in Q4 2023 and bottomed at $57.5 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $126.6 million, with a median of $116.8 million recorded in 2025.
  • On a YoY basis, Cash & Equivalents climbed as much as 297.27% in 2023 and fell as far as 69.55% in 2023.
  • Syndax Pharmaceuticals' Cash & Equivalents stood at $74.4 million in 2022, then surged by 297.27% to $295.4 million in 2023, then tumbled by 47.84% to $154.1 million in 2024, then fell by 12.43% to $134.9 million in 2025, then fell by 2.99% to $130.9 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $130.9 million, $134.9 million, and $116.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.